ENA Respiratory

ENA Respiratory is a clinical-stage pharmaceutical company headquartered in Melbourne, Australia, with operations in the USA. The company focuses on developing antiviral host defense enhancers to minimize the impact of symptomatic viral respiratory infections. Their lead product, INNA-051, is a once-weekly, dry powder nasal spray designed for self-administration, aiming to prime the body's natural antiviral defenses against various respiratory viruses. ENA Respiratory has received funding from investors such as Brandon Capital, The Minderoo Foundation, Uniseed, and Flu Lab, and has established partnerships with organizations like the U.

• Healthtech

Visit website ↗